Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

Strong recommendations presented for tapinarof cream, roflumilast cream, lebrikizumab, nemolizumab with concomitant topical therapy.

Arcutis is financially strong, with over 30 months of cash runway. The atopic dermatitis market is large and shifting away from steroids. See more on ARQT here.

Rezpegaldesleukin, an investigational interleukin-pathway agonist, demonstrated efficacy and safety for people with moderate to severe atopic dermatitis, meeting its primary and secondary ...

The Phase 1b trial is designed to evaluate the safety, tolerability, pharmacokinetics, target engagement, and early signs of efficacy of ENV-294 in patients with moderate to severe atopic dermatitis.

Dupilumab treatment in atopic dermatitis patients shows a 58% higher risk of developing psoriasis compared to other systemic treatments. The number needed to harm is 94, indicating a limited ...

Corvus Pharmaceuticals announced interim data from its Phase 1 clinical trial of soquelitinib for moderate to severe atopic dermatitis, indicating that Cohort 3 (200 mg BID) showed earlier and ...

About Atopic Dermatitis Atopic dermatitis (AD) is the most common type of eczema, affecting approximately 10 million children and 17 million adults in the United States.

Researchers found a causal association between insomnia and atopic dermatitis and identified several genetic variations contributing to the association.

Atopic dermatitis causes flaky, itchy, dry, and inflamed skin. It can look different on darker skin, making it harder to spot or treat.

Allais, B. and Friedman, A. (2020) ARTICLE Colloidal Oatmeal Part I History, Basic Science, Mechanism of Action, and Clinical Efficacy in the Treatment of Atopic Dermatitis. Journal of Drugs in ...

Atopic dermatitis in a darker skin tone can come with key differences in symptoms, delays in diagnosis, and treatment challenges. Here’s what to know.